Target family: CD molecules (type: other_protein)
Target: CD3e

Ligand: ZWB67 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8 pKd
Reference (Journal): Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab&#xae; bispecific antibody against solid tumors.
Published in: Immunobiology

Ligand: tepoditamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 6.75 pKd
Reference (Journal): Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML
Published in: Blood

Ligand: teplizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): In vitro characterization of five humanized OKT3 effector function variant antibodies.
Published in: Cell Immunol

Ligand: teplizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
Published in: Int Immunopharmacol

Ligand: tarlatamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2024)
Primary target: no
Median affinity: 8.359999656677246 pKd
Reference (Journal): AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Published in: Clin Cancer Res

Ligand: PF-07062119 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.619999885559082 pKd
Reference (Journal): A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Published in: Clin Cancer Res

Ligand: PF-07062119 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.619999885559082 pKd
Reference (Journal): A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Published in: Clin Cancer Res

Ligand: otelixizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
Published in: Eur J Immunol

Ligand: muromonab-CD3 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (1992)
Primary target: yes
Median affinity:  -
Reference (Journal): Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Published in: Transplant Proc

Ligand: mosunetuzumab (Antibody)
Interaction type: Antibody
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Published in: Sci Transl Med

Ligand: linvoseltamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.920000076293945 pEC50
Reference (Journal): A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
Published in: Blood Adv

Ligand: epcoritamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA & EMA (2023)
Primary target: no
Median affinity:  -
Reference (Journal): DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Published in: EBioMedicine

Ligand: catumaxomab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA (2009)
Primary target: yes
Median affinity:  -
Reference (Journal): Catumaxomab: clinical development and future directions.
Published in: MAbs

Ligand: blinatumomab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Primary target: no
Median affinity: 7 pKd
Reference (Journal): Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Published in: Int J Cancer

Ligand: AX-024 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.
Published in: Sci Transl Med